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A Naval Postgraduate School (NPS) applied physics associate professor has just been
awarded a patent that could potentially revolutionize the treatment of cancer.
Dr. Emil Kartalov received the patent, March 20, for work he did at the University of Southern
California (USC) to use a biochemical method – microfluidics – to mark the DNA of mutated
cancer cells.
“In other words, it’s like taking a tiny little pencil to write down the coordinates on the exact
piece of DNA so that it can later be analyzed,” Kartalov explained. “We can tell how many of
them there are and where they came from by these coordinates, and suddenly we have an
enormous amount of information to work with.”
Time is a critical component in fighting cancer, and Kartalov says this process can dramatically
reduce the gap between initial diagnosis and successful treatment.
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Currently, targeted therapies are quite effective at decimating cancerous cell populations. The
problem, however, is that nature always finds a way ... 99 percent might be eradicated, but
that remaining one percent can lead to a resurgence which overwhelms the patient.
“The few mutants that are resistant have found a way around [the targeted therapy], they’ve
short-circuited it somehow,” Kartalov said. “Suddenly those guys are going to repopulate and
they potentially can kill the patient.
Oncologists often chalk this up to ‘acquired resistance,’ but Kartalov says the resistance was
already there. Mutations will always exist for any given population; the key is being able to
identify them.
Studying DNA sequences is the easy part ... Since the 1980s, a process known as
Polymerase Chain Reaction (PCR) has been available to efficiently make copies, like a
Xerox machine, of focused segments of DNA. The difficulty comes in when incorrect DNA gets
amplified through the PCR process.
“Essentially, you are trying to see only a particular page of a book, but the Xerox machine can
fail and instead start copying the rest of the book,” Kartalov explained. “Then you miss the
critical page.”
Kartalov’s patent circumvents this. Instead of replicating an entire sample, it
compartmentalizes it into little volumes, allowing reactions to be done for each. Using
microfluidics, coordinates are assigned to each tiny chunk so that they can be isolated and
studied in turn.
“Now, when you amplify the sample, you only compete with another hundred cells rather than
a hundred thousand cells,” he explained. “You’re tilting the playing field in your favor so that
you can identify the particular mutation much more easily.”
Being able to identify how many mutations exist, and where they are, opens the door to a
wealth of information on how the disease changes and adapts in the individual patient.
Interesting questions on this morphology can now be addressed. What is the concurrence of
different mutations and where do they happen? Do they happen only in the cancer or in normal
tissue?
The answers to these questions and others means more efficiently tailored treatment.
“So instead of the patient being a guinea pig, you already know which drugs are going to work
and which ones are not going to work,” Kartalov said. “That way, as they’re running out of
time, you can actually address it in a much more intelligent and well-designed manner.”
Kartalov filed the patent a number of years ago while an assistant professor at USC. In 2016,
he came to NPS and became a civil servant, thus precluding any involvement in commercial
development of the technology due to potential conflict of interest.
“But that’s OK,” he laughed. “It was a reasonable sacrifice to become part of the NPS team,
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and it’s a trade-off I’m not unhappy about.”
Others will take up the ideas of the patent and move the ball forward, and Kartalov has turned
to integrating his biotech background into interdisciplinary endeavors with military applications.
He currently is developing insulation for next-generation divers’ suits with greater endurance
and less susceptibility to hypothermia. On the horizon are exoskeletal suits enabling great
strength and endurance to service members, not unlike Marvel Comics’ Iron Man.
When asked about the personal significance of his latest patent, Kartalov smiled and quoted
Horace, “Exegi monumentum aere perennius,” which translates to, “I have made a monument
more lasting than bronze.
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